The latest cancer drugs news
Browsing: Cancer Drug News
First test of anti-cancer agent PAC-1 in human clinical trials shows promise
A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in…
FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer
On December 16, 2022, the Food and Drug Administration approved nadofaragene firadenovec-vncg for adult patients with…
Palbociclib combination in advanced breast cancer: Again only disadvantages
Palbociclib in combination with an aromatase inhibitor is, among other therapeutic indications, approved for first-line…
New ‘capsules’ aim to deliver more effective targeted cancer drug therapies
Australian and New Zealand researchers have developed tiny metal ‘containing capsules’ for targeted delivery of…
Study shows promise of new anti-KRAS drug for pancreatic cancer
A small molecule inhibitor that attacks the difficult-to-target, cancer-causing gene mutation KRAS, found in nearly 30…
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
The Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx for adult patients with folate…
FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer
The Food and Drug Administration approved cemiplimab-rwlc in combination with platinum-based chemotherapy for adult patients with…
FDA approves brentuximab vedotin in combination with chemotherapy for paediatric patients with classical Hodgkin lymphoma
The Food and Drug Administration approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and…
NICE final draft guidance adds further treatment option for triple-negative breast cancer
NICE has published the final draft guidance which recommends pembrolizumab as an option for people…
Zanubrutinib receives European commission approval for the treatment of adults with marginal zone lymphoma
European Commission (EC) has granted marketing authorization of zanubrutinib for the treatment of adult patients…